Business Wire India

Delivered Year-over-Year Growth in Reported Revenue of +18.4% and Underlying Revenue of +3.8%, Driven by 14 Global Brands

Grew Reported Operating Profit of 248.6 Billion Yen ($2.2B) and Solid Underlying Core Operating Profit Margin of 30.5% While Increasing R&D Investments

Paid 242.9 Billion Yen Toward $2.2 Billion of Debt in Q1 and Company Expects to Pre-pay a Total of Approximately 450 Billion Yen (~$4.1B) of Debt in FY2021

Anticipated Inflection Year for the Pipeline with Five to Six Regulatory Submissions and Seven New Molecular Entities in Pivotal Studies by Fiscal Year-End

Confirms Full-year FY2021 Management Guidance and Forecast

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021).…